• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN SA Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Small Efficacy Differences Between Atypicals in Treating Schizophrenia

Small Efficacy Differences Between Atypicals in Treating Schizophrenia

April 1, 2009
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Section editor, Glen Spielmans, PhD

A recent meta-analysis examined all blinded clinical trials that directly compared second-generation antipsychotics, including 76 trials with 13,558 participants. The authors used the Positive and Negative Syndromes Scale (PANSS) as their primary outcome measure. On the PANSS, several differences emerged: olanzapine was signifi- cantly superior to aripiprazole, quetiapine, risperidone, and ziprasidone; risperidone outperformed quetiapine and ziprasidone. Fewer studies reported data separately on positive and negative symptoms. For positive symptoms, olanzapine and risperidone again outperformed quetiapine and ziprasidone. When considering only negative symptoms, quetiapine was superior to clozapine; no other significant differences emerged. In terms of dropout from trials due to ineffica- cy, olanzapine again outperformed risperi- done, ziprasidone, and quetiapine while clozapine was superior to risperidone (Leucht S et al., Am J Psychiatry 2009; 166:152-163).

TCPR’s Take: Several statistically significant differences emerged between treatments, but they were small. For example, 16 patients would need to be treated with olanzapine rather than ziprasidone to avoid one dropout due to inefficacy. Other differences between treatments were of a similar magnitude; differences between olanzapine and risperidone were especially small. Only five studies included participants in their first episode of psychosis; no differences emerged in these studies. Treatment-resistant patients generally did not fare better on clozapine than comparator medications. However, clozapine patients on doses above 400 mg/day fared better than patients on risperidone. The authors stated they were surprised that clozapine did not consistently ourperform other antipsychotics, since other research has suggested that clozapine possesses superior efficacy relative to other atypicals for treatment-resistant patients, although this area of research remains controversial (McEvoy JP et al., Am J Psychiatry 2006;163:600-610).Pharmaceutical sponsorship was not related to outcomes. Differences in side effects and cost appear more substantial than differences in efficacy, so clinicians should carefully consider these factors when treating patients with schizophrenia.

General Psychiatry
KEYWORDS antipsychotics
    www.thecarlatreport.com
    Issue Date: April 1, 2009
    SUBSCRIBE NOW
    Table Of Contents
    Small Efficacy Differences Between Atypicals in Treating Schizophrenia
    Unclear Relationship Between SSRI Use and Gestational Hypertension
    Lamictal May Have Small Benefit for Bipolar Depression
    Health Care Reform: A Primer
    Insurance Issues in Psychiatry
    Monitoring Adverse Effects of Medications
    DOWNLOAD NOW
    Featured Book
    • PB4e_Cover2.png

      Psychiatry Practice Boosters, Fourth Edition (2023)

      Teaches you the key points of 63 of the most clinically relevant studies in psychiatry.
      READ MORE
    Featured Video
    • therapist_canstockphoto9201097.jpg
      General Psychiatry

      Using SAMe In Clinical Practice with Garrett Rossi, MD

      Read More
    Featured Podcast
    • canstockphoto6759394.jpg
      General Psychiatry

      Throwback Thursday: Brief Therapy for ADHD

      You started a stimulant medication for a young woman with ADHD. When she returns her symptoms are 70% better, but what can we do about the rest? Today a conversation with...

      Listen now
    Recommended
    • Approaches to Autism Intervention

      January 31, 2022
      canstockphoto2240982_child-bubbles_thumb.jpg
    • Currently Available Cannabis Products

      September 1, 2022
    • Interpreting Assessment Discrepancies from Multiple Sources

      October 17, 2022
      ChildAssessment.png
    • Approaches to Autism Intervention

      January 31, 2022
      canstockphoto2240982_child-bubbles_thumb.jpg
    • Currently Available Cannabis Products

      September 1, 2022
    • Interpreting Assessment Discrepancies from Multiple Sources

      October 17, 2022
      ChildAssessment.png
    • Approaches to Autism Intervention

      January 31, 2022
      canstockphoto2240982_child-bubbles_thumb.jpg
    • Currently Available Cannabis Products

      September 1, 2022
    • Interpreting Assessment Discrepancies from Multiple Sources

      October 17, 2022
      ChildAssessment.png

    About

    • About Us
    • CME Center
    • FAQ
    • Contact Us

    Shop Online

    • Newsletters
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN Self-Assessment Courses

    Newsletters

    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
    • The Carlat Hospital Psychiatry Report
    • The Carlat Geriatric Psychiatry Report
    • The Carlat Psychotherapy Report

    Contact

    info@thecarlatreport.com

    866-348-9279

    PO Box 626, Newburyport MA 01950

    Follow Us

    Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

    © 2023 Carlat Publishing, LLC and Affiliates, All Rights Reserved.